Effects of the dipeptidyl peptidase-IV inhibitor DAPT in vitro Vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired

glucose tolerance. Diabetes Care. 2008;31:30–5.PubMedCrossRef PRIMA-1MET molecular weight 9. He YL, Ligueros-Saylan M, Sunkara G, Vildagliptin, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol. 2008;48:85–95.PubMedCrossRef 10. Kadowaki T, Chujo M, Sagara R, et al. Clinical efficacy of monotherapy with vildagliptin in patients with type 2 diabetes: pooled data analysis from clinical trials in development phase in Japan. J New Rem Clin. 2011;60:217–30 (in Japanese). 11.

Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93:103–9.PubMedCrossRef 12. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab. 2008;10:931–8.PubMedCrossRef 13. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–55.PubMedCrossRef 14. Herman Thalidomide GA, NVP-BGJ398 manufacturer Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin

and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.PubMedCrossRef 15. Gastaldelli A, Nauck MA, Balena R. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism. 2013;62:1330–9.PubMedCrossRef 16. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79:291–8.PubMedCrossRef 17. Ohkura T, Fujioka Y, Sumi K, et al. Sitagliptin improves the impaired acute insulin response during a meal tolerance test in japanese patients with type 2 diabetes mellitus. Diabetes Ther. 2014;5:285–97.PubMedCentralPubMedCrossRef”
“1 Introduction Type 2 diabetes mellitus (T2DM)—a chronic and progressive disorder that is characterized by the insufficient production of insulin and/or reduced responsiveness to its effects—is difficult to effectively treat long-term [1].